Pinned Tweet
TIL that even David Sinclair supports Manhattan Project to defeat aging. It seems everyone in community supports it, and it would receive massive support and media attention.
I think every our next conference on aging, whether it's Vitalist Bay or Dublin Longevity conference, or RAADfest, should issue a joint statement requesting Manhattan Project to defeat aging. teapawt.org/davidasinclair/status/…
Vladimir Shakirov retweeted
maybe mathematics was always something trivial, like chess, rather than something difficult, like laundry
Vladimir Shakirov retweeted
PRESIDENT TRUMP: "It's not artificial intelligence. It's not artificial, it's super. Problem is, it may be too super.
So, President Xi and I agreed that we're gonna do some joint guardrails, the two of us."
Vladimir Shakirov retweeted
Nick Bostrom this morning on superintelligence slaying the Dragon‑Tyrant, and on the cost of waiting too long:
Vladimir Shakirov retweeted
JUST IN: Riemann Hypothesis has been solved.
alpo.ge/remark.pdf
Vladimir Shakirov retweeted
Wow, that is serious firepower and absolutely incredible fundraising productivity. If you convert this amount of capital into drug candidates at the most expensive $5mil per PCC (includes non-GLP tox) - that enough for 1,000 new drug candidates.
And I am very happy to hear this - it is better than putting money into simple scaling of generalist AI.
Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...
Vladimir Shakirov retweeted
Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...
Vladimir Shakirov retweeted
The AI Futures Project have updated their timelines. They say we are five months ahead of AI 2027, and they now believe a Superhuman AI Researcher will arrive sometime in 2027.
Vladimir Shakirov retweeted
When we launched the Remote Labor Index a year ago with @ScaleAILabs , the best AI could fully automate 2.5% of real freelance projects. Fable 5.2 now automates 41.3%.
The automation rate is doubling every ~3 months. AIs may soon be able to do all remote work faster and more cheaply than humans.
Vladimir Shakirov retweeted
Last night an AI agent performed brain surgery on a mouse.
We gave it 19 gene therapy vectors in a spreadsheet, a mouse model of epilepsy, access to a motorize surgery rig with cameras and one goal: reduce seizures.
It picked the drug. It picked the brain region. It derived the coordinates from three papers. Then it drove the stereotaxic arms into the brain and injected 250 nanolitres while watching the entry site through the rig camera for bleeding.
A licensed vet gated every irreversible step and held a physical kill switch to stop the AI agent.
Thread on what it decided, what it saw, and the moment it refused to let me override it.
[Writing this on the spot out of excitement, but I've been 18hrs in front of my laptop coding and coordinating this, so keeping it brief and descriptive, more cohesive thoughts on this soon...]
Vladimir Shakirov retweeted
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own.
In doing so, we’ve learned much more about how Claude can support the many stages of drug development.
In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences.
anthropic.com/research/early…
I would really like to see this type of evaluation for every biomedical paper, review, and meta-review.
Tyler Cowen:
'I am not even sure what to say at this point. We need a radical revaluation of this work, and of the associated policy arguments. More generally, this is only a single step in the story of how AI is going to revise economic science, and indeed past research more generally. As I stress in many of my recent talks, there will be significant gains and losses in status, with the losses often outweighing the gains. I see this as one of those cases.'
2
175
If you look closely enough, breakthroughs in everything are accelerating exponentially.
An exponential always starts off looking small.
this might be my last normal tweet before biotech goes vertical
i'm not a whistleblower. I don't work at Lilly, Novo or any of the big labs
but there is a massive shift happening in human biology right now.
it's sitting in press releases and almost nobody reads them
the last 6 months alone:
- a once-daily pill roughly doubled median survival in metastatic pancreatic cancer (13.2 vs 6.6 months)
- a one-time gene editing infusion cut hereditary angioedema attacks 87%, and 62% of patients stayed attack-free and off all other prevention for 6 months
- a one-time gene edit for cholesterol dropped LDL up to 62%, and it held for over a year
- a personalized mrna vaccine beat keytruda alone in a 1,137 patient melanoma phase 3
- retatrutide hit ~28% weight loss in a phase 3
- an ai-designed drug entered phase 3
- a pill that regrows hair passed its second phase 3
- an immunotherapy that could let some rectal cancer patients skip surgery, chemo and radiation just got fda approved
- a man lived 271 days off dialysis on a pig kidney
- human cells were caught passing chromosome-sized chunks of DNA to their neighbors, and it changes how the neighbors behave
we are on the verge of an era where the human body is a software problem and the update cycle gets shorter everyday
stick around, it's going to get weird
bio/acc
Vladimir Shakirov retweeted
Sam Altman's one-person company prediction is coming true. Anthropic just bought one. The founder of Mithril Medicine used Claude to take a muscular dystrophy antibody treatment from concept to proof-of-principle in mice in 18 months, with just himself, Claude, and part-time consultants. The technical report is great. I will quote:
'The week opened with the handover of two cell-based assays, cell adhesion and flow cytometry, within our team, while eleven questions remained open with the assay CRO. In two sentences, one of us asked Claude to review the latest emails between the outgoing assay lead and the assay CRO and to recommend next steps for the handover, and gave it the link to the handover folder. Claude returned a bottom line after 96s and a full plan with five drafted emails after 18 min. For the full plan it read six email threads, the handover folder, two slide decks and two reports, all in the mailbox and file store to which we had given it access. Four working days later, nine of the eleven questions had an answer in writing and the other two had been left to pilot experiments. The adhesion screen was thereby set out in writing. The CRO drew the plate map to the format that our team had requested, Claude compiled the run order and the material calculation from the production data, and one of us reviewed and approved them.
On day 4, the production CRO delivered its data package, a report of 341 pages, which one of us forwarded to Claude in two sentences, with the request to review it, share observations and recommend next steps. Claude returned a bottom line after 2 min 40s and, once it had read every page, a visual synthesis of all 113 constructs after 7 min 53s. The synthesis arranged the constructs on the grid of 14 by 8 arms. Claude marked 82 constructs for screening as is, seven for additional polishing, and the 24 constructs of three laminin-binding arms to be held back from the cell-based assays on production criteria. Each of the 113 constructs thus had a proposed next step in less than 8 min.
Claude had recommended binding kinetics for all 113 con-structs, and on day 7 one of us challenged this plan. Claude defended it within 27s, arguing that affinity would show whether the three arms merit further work. One of us overruled this recommendation and set the three arms aside on production criteria. Their material remains in storage. Four minutes later, Claude had revised its memo, the working page, the run order and three unsent drafts from 113 to 89 constructs. It had also applied the ruling to three dependent steps in the unsent drafts, each flagged for our veto. The exchange took 7 min 36s from challenge to new plan, and every affected email was still an unsent draft. After the ruling, eight emails drafted by Claude went out on the same day to three CROs and a consultant.
Over the whole week, Claude drafted 17 emails, each in answer to a request from one of us, and we sent 12 of them, each after editing. With its drafts, Claude listed 41 points, such as tube fills, shipping conditions, recipients and assay settings, for which it had found no written statement of ours, so that we could confirm, change or strike each before sending. We kept some, struck others and changed one. Among the passages that we kept were proposals for controls. One draft proposed a comparison of polished and unpolished material on one sensor chip, to size the error that impurities cause in the rest of the panel. Another requested a buffer control diluted like the most dilute sample, so that any effect of the buffer appears at its largest. These proposals concerned the measurement of constructs that had already been produced, and each reached a CRO only after one of us had reviewed and approved it.
Vladimir Shakirov retweeted
OpenAI has announced to three new discoveries in mathematics, computer science, and physics:
- Local smoothing and the Kakeya conjecture
- The Exponential Time Hypothesis is false
- Existence of quantum chromodynamics and completions of the Standard Model
I hate it when I am trying to search and rescue a lost hiker and he keeps frantically running from cover to cover in a dense forest area, trying his hardest to avoid my helping drone and prolong his suffering out of pure instinct
Purdue University's IDEAS Lab built an autonomous drone that tracks runners through dense forests completely without GPS or cloud networks.
By running 3D LiDAR mapping and obstacle-avoidance AI entirely on-chip, it can weave under tree canopies and predict target movement through blind spots in real time.
Massive implications for next-gen search & rescue and edge AI.

































